Research and Markets: Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companies & 13 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/5qvdpr/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Companies Involved in Therapeutics Development

  • Shionogi & Co., Ltd.
  • AstraZeneca PLC
  • Cubist Pharmaceuticals, Inc.
  • Progenics Pharmaceuticals, Inc.
  • Cosmo Pharmaceuticals S.p.A
  • Theravance, Inc.
  • Sucampo Pharmaceuticals, Inc.
  • AIKO Biotechnology, Inc.
  • Synergy Pharmaceuticals, Inc.
  • S.L.A. Pharma AG
  • Develco Pharma Schweiz AG

Drug Profiles

  • naloxegol
  • lubiprostone
  • methylnaltrexone bromide
  • naldemedine
  • bevenopran
  • naloxone hydrochloride PR
  • methylnaltrexone bromide
  • TD-1211
  • naloxone hydrochloride SR
  • SP-333
  • naloxone hydrochloride
  • (6-beta-naltrexol + oxycodone)

For more information visit http://www.researchandmarkets.com/research/5qvdpr/opioidinduced

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology